StoneX Issues Positive Forecast for Agilon Health (NYSE:AGL) Stock Price

Agilon Health (NYSE:AGL) had its target price boosted by StoneX from $140.00 to $145.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts also recently commented on AGL. Royal Bank Of Canada set a $125.00 price objective on shares of Agilon Health in a research report on Tuesday, September 15th. Barclays set a $111.00 price target on Agilon Health and gave the company an “equal weight” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. increased their target price on shares of Agilon Health from $31.00 to $85.00 and gave the stock an “underweight” rating in a report on Monday, August 24th. Sanford C. Bernstein upgraded Agilon Health from a “market perform” rating to an “outperform” rating and increased their price target for the company from $86.00 to $125.00 in a research note on Tuesday, September 15th. Finally, Benchmark reiterated a “buy” rating and set a $140.00 target price (up from $95.00) on shares of Agilon Health in a research report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $105.54.

Agilon Health Stock Up 1.1%

Shares of NYSE AGL opened at $114.77 on Wednesday. The stock has a market capitalization of $1.93 billion, a P/E ratio of -20.68 and a beta of 3.10. The stock’s fifty day moving average is $89.65 and its 200 day moving average is $68.07. Agilon Health has a 52 week low of $7.48 and a 52 week high of $133.04. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.13 and a current ratio of 1.13.

Agilon Health (NYSE:AGL) last issued its earnings results on Wednesday, November 4th. The company reported $1.97 EPS for the quarter, beating the consensus estimate of ($1.23) by $3.20. Agilon Health had a negative net margin of 1.45% and a negative return on equity of 51.97%. The company had revenue of $1.52 billion during the quarter, compared to analysts’ expectations of $1.46 billion. Sell-side analysts forecast that Agilon Health will post -2.90 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Tidal Investments LLC acquired a new position in shares of Agilon Health during the second quarter valued at about $1,405,000. Rubicon Founders LLC acquired a new stake in shares of Agilon Health in the 2nd quarter valued at about $11,290,448. State Street Corp acquired a new stake in shares of Agilon Health in the 2nd quarter valued at about $30,024,000. Ellsworth Advisors LLC bought a new stake in Agilon Health in the 3rd quarter valued at about $809,000. Finally, Great Lakes Advisors LLC bought a new stake in Agilon Health in the 2nd quarter valued at about $702,000.

Agilon Health Company Profile

Agilon Health is a U.S. healthcare company that partners with primary care physicians to provide care for patients enrolled in Medicare Advantage plans. Its model is designed to help physician groups move from traditional fee-for-service care toward value-based care, in which providers are rewarded for improving patients’ health and coordinating their care. The company provides participating physician groups with clinical, operational, technology and administrative support, along with resources to manage patient populations and coordinate care across local healthcare networks.